Truist Securities Reiterates Buy on Adverum Biotechnologies, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a 'Buy' rating on Adverum Biotechnologies (NASDAQ:ADVM) and maintained a $6 price target.
September 05, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adverum Biotechnologies has been reiterated with a 'Buy' rating by Truist Securities, with a maintained price target of $6.
The 'Buy' rating from Truist Securities indicates a positive outlook for Adverum Biotechnologies. This could potentially attract investors, driving up the stock price in the short term. The maintained price target of $6 also suggests that the analyst believes the stock is currently undervalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100